Nykode Therapeutics ASA

DelveInsight's 'Melanoma Pipeline Insight 2024' covers 150+ companies and 170+ pipeline drugs, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, and BioNTech SE. Key therapies like Amtagvi (Iovance Biotherapeutics) received FDA fast-track approval in 2024 for metastatic melanoma. Neoadjuvant immunotherapy became standard care for stage III melanoma after ESMO 2024 updates. The report assesses therapies by product type, stage, route of administration, and molecule type, highlighting active and inactive pipeline products.

Richter Biologics inaugurates P2 unit with 1,500 l and 300 l production lines, targeting commercial production for a big pharma company from 2025. The company plans a 3,000 l line for a phase II antibody product. Richter Biologics postpones US expansion and focuses on organic growth in microbial production. Gedeon Richter invested €95m in the expansion, benefiting from German biotech redundancies. Richter Biologics aims to continue growing and filling its pipeline with innovative biotech products.